In a nutshell This study assessed the accuracy of whole-body (WB) magnetic resonance imaging (MRI) in evaluating the treatment response of blood cancers. The data indicated that WB-MRI had a high diagnostic performance for assessing the treatment response of blood cancers and its addition was strongly linked to better diagnostic sensitivity. Some...
Read More
In a nutshell This study reported the final effectiveness and safety of subcutaneous (SC) injections versus intravenous (IV) infusions of daratumumab (Darzalex) in patients with relapsed or refractory multiple myeloma (MM). The data showed that daratumumab SC injections were as effective and caused fewer side effects than IV infusions over the long term...
Read More
In a nutshell This study investigated the effectiveness and safety outcomes of administering radiotherapy (RT) at the same time as DCEP salvage chemotherapy in patients with unresponsive multiple myeloma (MM). This study concluded that RT administered at the same time with DCEP salvage chemotherapy was effective and well-tolerated by most of the...
Read More
In a nutshell This study evaluated the effectiveness of daratumumab (Darzalex)-containing regimens in patients with multiple myeloma (MM) unresponsive to lenalidomide (Revlimid) maintenance therapy. The data showed that daratumumab-containing therapies are effective regimens in these patients. Some background Multiple myeloma (MM) is a type...
Read More
In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell The study aimed to investigate the rate of response (seroconversion) to SARS-Cov-2 vaccination in patients with blood cancers. This study concluded that seroconversion rates in these patients were significantly lower than that of healthy controls. Some background The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)...
Read More
In a nutshell This study evaluated the effectiveness of salvage autologous hematopoietic cell transplantation (ASCT) performed with stem cells obtained after previous transplantation in patients with relapsed multiple myeloma (MM). The data showed that salvage ASCT performed with stem cells remobilized after previous transplantation is a good treatment...
Read More
In a nutshell This study evaluated the long-term effectiveness and safety of isatuximab (Sarclisa) in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (Decadron) (Pd) in previously treated patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that isatuximab plus Pd combination significantly improved the...
Read More
In a nutshell This study evaluated the effectiveness and safety of etoposide (Etopophos) combined with cytarabine (Cytosar-U) plus granulocyte colony-stimulating factor (G-CSF, Neupogen) in patients with multiple myeloma (MM) for stem cell mobilization. The data showed that etoposide combined with cytarabine plus G-CSF was safe and effective for the...
Read More
In a nutshell The study aimed to investigate if immunocompromised patients with blood cancers benefit from COVID-19 vaccination. This study concluded that these patients should not be excluded from COVID-19 vaccination. Some background Patients with blood cancers are at high risk for severe forms of COVID-19 disease due to lower immune...
Read More
In a nutshell This study evaluated the effectiveness and safety of an all-oral combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone (Decadron) in transplant-eligible patients with newly diagnosed multiple myeloma (MM). The data showed that this combination was effective with manageable side effects in these...
Read More
In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro)-dexamethasone (Decadron) (ixa-dex) versus pomalidomide (Pomalyst)-dexamethasone (pom-dex) combination for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that ixa-dex was safe and as effective as pom-dex...
Read More
